Takeda
TAK Big PharmaTakeda is a major pharmaceutical company focused on Immunology, Metabolic, Gastroenterology. Key products include ENTYVIO.
FDA Novel Drug Designations
(2017-2023)See 5 novel approvals →
Takeda at a Glance
- Leading 6 drug targets across portfolio
- Fast trial execution (17 months median completion)
Takeda's Key Drugs
Takeda's core commercial portfolio centers on ENTYVIO, ICLUSIG, LIVTENCITY, spanning Immunology and Metabolic — its most strategically important drugs approved in the last 15 years.
Ulcerative Colitis
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Cytomegalovirus Infection
Non-Small Cell Lung Cancer
Colorectal Cancer
Takeda's Recent FDA Approvals
Takeda secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Takeda's Therapeutic Areas
Takeda's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Metabolic, across 18 biologic and 35 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Takeda's Top Competitors
Takeda's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Sanofi, and Amgen. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Takeda Pipeline Snapshot
Takeda has 312 active clinical programs from ClinicalTrials.gov — 142 Phase 3, 62 Phase 2 and 108 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 154/220 completed
- • Speed: 17 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (22)
Discontinued (5)
Company Info
- First Approval
- 1945-10-04
- Latest
- 2026-08-28
- Applications
- 93
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges